Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Industry News

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

August 01, 2025

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

Todd Neale

February 27, 2025

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Industry News

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

November 14, 2017

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Industry News

Boston Heart Reaches Milestone in Statin Intolerance Testing

September 08, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

Advertisement

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

ACC/AHA Release New Comprehensive ACS Guidelines

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Heterozygous FH Diagnosed Late, Remains Undertreated

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Boston Heart Reaches Milestone in Statin Intolerance Testing

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content